PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515371
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515371
AAV Contract Development and Manufacturing Organizations Market size was valued at USD 677.56 Million in 2023, expanding at a CAGR of 16.9% from 2024 to 2032.
Adeno-associated viruses (AAVs) are small, non-pathogenic viruses famous for their utility as vectors in gene therapy and biomedical research. They are characterized by their ability to infect cells and deliver genetic material without causing disease in humans. AAV vectors are increasingly being used in the clinic to treat a wide range of diseases and tissues such as Parkinson's disease and Peripheral nerve regeneration.
AAV Contract Development and Manufacturing Organizations Market- Market Dynamics
Increasing gene therapy trials elevate AAV vector requirements.
The global market for viral vector Contract Development and Manufacturing Organizations (CDMOs) is poised for significant growth in the coming years, driven by advancements in gene therapy and increasing investments by governments and leading market players. This growth is primarily fueled by rising demand for adeno-associated virus (AAV) vectors in gene therapy R&D, highlighting the pivotal role played by AAV CDMOs in their production and manufacturing.
Government investments in innovative technologies and manufacturing facilities further contribute to market expansion. Novel technologies such as automation, cloud computing, industrial robotics, artificial intelligence, and the Internet of Things are making manufacturing processes more efficient. Adeno-associated virus (AAV) CDMOs provide specialized expertise and infrastructure crucial for supporting the biopharmaceutical industry, ensuring efficient production of AAV vectors to meet the growing demand. With these factors in play, the AAV CDMOs market is set to witness robust growth throughout the forecast period, driven by the increasing adoption of gene therapy and advancements in biopharmaceutical manufacturing.
AAV Contract Development and Manufacturing Organizations Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.9% over the forecast period (2024-2032)
Based on Workflow segmentation, Downstream Processing was predicted to show maximum market share in the year 2023
Based on Culture Type segmentation, Adherent Culture was the leading type in 2023
Based on Therapeutic Area segmentation, Neurological disorders were the leading type in 2023
Based on the Method, in vivo was the leading type in 2023
Based on Application, Cell & Gene Therapy was the leading type in 2023
Based on End User segmentation, Pharmaceutical Companies were the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global AAV Contract Development and Manufacturing Organizations Market is segmented based on Workflow, Culture Type, Therapeutic Area, Method, Application, End User, and Region.
The market is divided into two categories based on Workflow: Upstream Processing and Downstream Processing. Downstream processing refers to the purification, concentration, and formulation steps involved in isolating and refining AAV vectors after they have been produced in cell culture. This includes processes such as cell lysis, clarification, chromatography (e.g., affinity chromatography, ion exchange chromatography), filtration, and formulation. The dominance of downstream processing in the AAV vector sector is due to the critical need to purify and concentrate AAV vectors to achieve high-purity and high-titer vector preparations suitable for clinical use. Downstream processing ensures that AAV vectors are free from contaminants and impurities, maintain stability, and are formulated in a manner that enhances their safety, efficacy, and storage stability.
The market is divided into four categories based on Culture Type: Adherent culture and Suspension Adherent cultures involve growing cells that attach to a treated surface, forming a single layer. This method is ideal for studying animal cells but limits them to a flat, 2D environment, unlike their natural form. While useful for various applications, adherent cultures can be limited in terms of scalability due to their surface area dependence.
AAV Contract Development and Manufacturing Organizations Market- Geographical Insights
The AAV gene therapy sector is experiencing significant growth in North America, driven by several key factors. Firstly, the region hosts a substantial number of research centers and institutes dedicated to advancing gene therapy technologies. These institutions play a pivotal role in conducting cutting-edge research and development and fostering innovation in AAV vector technologies and therapeutic applications. Their collective efforts contribute to the robust pipeline of novel therapies targeting a wide range of genetic disorders, neurodegenerative diseases, and cancers.
Additionally, federal agencies in North America have allocated substantial investments to bolster the local cell and gene therapy research infrastructure.
Major players in the market are Thermo Fischer Scientific, Inc., Oxford Biomedica, Charles River Laboratories International, Inc., Creative Biogene, GenScript ProBio, Merck KGaA, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Lonza, Curia Global, Inc., and Takara Bio Inc. These companies, among many others, play a crucial role in advancing and expanding the AAV vector manufacturing market. Their collective efforts underscore their critical contribution to the development of gene therapy and its potential to revolutionize medical treatments.
In May 2024, Andelyn Biosciences was selected to manufacture AAV therapies under CIRM, aimed to advance BGTC's mission to develop platforms and standards and propel the development and delivery of customized gene therapies for millions affected with rare diseases.
In Feb 2024, Charles River Laboratories International, Inc. introduced reference materials for its adeno-associated virus (AAV) and lentiviral vector (LVV) portfolio, aimed at enhancing the efficiency of Cell and Gene Therapy (CGT) research and development as it transitions to Good Manufacturing Practice (GMP) standards.
GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Thermo Fisher Scientific, Inc.
Catalent Inc.
Charles River Laboratories International, Inc.
Danaher (Aldevron)
Merck KGaA
Biovian Oy
Esco Lifesciences (Esco Aster Pte. Ltd.)
GenScript ProBio
Takara Bio, Inc.
Oxford Biomedica
Belief Biomed, Inc.
Forge Biologics